Angiosyn's Acquisition

Angiosyn was acquired by Pfizer on January 21, 2005.

Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis. The company's initial therapeutic indication is for ophthalmic diseases, such as macu…

Articles about Angiosyn's Acquisition: